pravastatin (Pravachol)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Pravachol.

Indications

Contraindications

pregnancy category = x

safety in lactation = -

Dosage

Pharmacokinetics

elimination via liver

protein binding = 50 %

1/2life = 1.6-3 hours

Monitor

(see HMG CoA reductase inhibitor)

Adverse effects

Drug interactions

Mechanism of action

More general terms

Additional terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1990. pg 882
  3. Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001
  4. 4.0 4.1 Physician's Desk Reference (PDR) 54th edition, Medical Economics, 2000
  5. 5.0 5.1 5.2 Prescriber's Letter 9(1):1 2002
  6. 6.0 6.1 6.2 Prescriber's Letter 9(9):49 2002
  7. 7.0 7.1 7.2 Mizuno K et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation 2008 Jan 29; 117:494. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18172039
  8. 8.0 8.1 Prescriber's Letter 16(8): 2009 Clinically Significant Statin Drug Interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250812&pb=PRL
  9. 9.0 9.1 Medical Knowledge Self Assessment Program (MKSAP) 16, American College of Physicians, Philadelphia 2012
  10. Carter AA et al. Risk of incident diabetes among patients treated with statins: Population based study. BMJ 2013 May 23; 346:f2610. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23704171
    Huupponen R and Viikari J. Statins and the risk of developing diabetes. BMJ 2013 May 23; 346:f3156 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23709567
  11. Deprecated Reference
  12. 12.0 12.1 12.2 12.3 12.4 12.5 12.6 12.7 Wiggins BS, Saseen JJ, Page RL 2nd et al Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease. A Scientific Statement From the American Heart Association. Circulation. 2016;134:00-00 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27754879 <Internet> http://circ.ahajournals.org/content/circulationaha/early/2016/10/17/CIR.0000000000000456.full.pdf

Database